Panbela Therapeutics, Inc. (OTCPK: PBLA)
Health Care · Biotechnology · US
$0.00
+9900.00% today · -99.9% 1Y
Panbela Therapeutics, Inc. (OTCPK: PBLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $485.00 and employs 8 people.
Over the last twelve months the share price has lost 99.9%, trading between 0.00 and 2.50.
Tweenvest scores Panbela Therapeutics, Inc. across four factors: quality 1/100. Its strongest factor is quality.
PBLA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $485.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -11.31
- Dividend yield
- —
- Beta (5Y)
- 43.59
- 52-week high
- $2.50
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 4.85M
- Employees
- 8
- Next earnings
- —
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
- ISIN
- US69833W4042
- Founded
- 2011
- Listed since
- Jan 3, 2017
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.